

SPAIIN Guidance for the Annual Review of Children and Adolescents' Living with HIV

#### NOTE

This guideline is not intended to be construed or to serve as a standard of care. Standards of care are determined on the basis of all clinical data available for an individual case and are subject to change as scientific knowledge and technology advance and patterns of care evolve. Adherence to guideline recommendations will not ensure a successful outcome in every case, nor should they be construed as including all proper methods of care or excluding other acceptable methods of care aimed at the same results. The ultimate judgement must be made by the appropriate healthcare professional(s) responsible for clinical decisions regarding a particular clinical procedure or treatment plan. This judgement should only be arrived at following discussion of the options with the patient, covering the diagnostic and treatment choices available. It is advised, however, that significant departures from the national guideline or any local guidelines derived from it should be fully documented in the patient's case notes at the time the relevant decision is taken.

Sections	Page
1. Immunisation	3 and 4
2. Metabolic and Renal	5 and 6
3. Growth and Puberty	7
4. Neurodevelopment and Education	8
5. Disclosure and Adherence	9, 10, 11 and 12
6. Sexual Health	13

SPAIIN Guidance for the Annual Review of Children and Adolescents' Living with HIV

Name	CHI Number
DOB	Date of Review

#### 1. Immunisation Section

Before completing this section, please refer to previous immunisation records / annual reviews.

#### Varicella immunisation (over 1 year of age)

Clinical history of VZV? YES NO	
Date of VZV immunisation://	
Is there a presence of VZV IgG? YES	Enter Level
NO	Consider VZV immunisation (dependant on current CD4 count – discuss with responsible physician)
NOT CHECKED	Please test for presence.
	Date: / /

#### Hepatitis B Immunisation

YES

NO

Has a course of Hepatitis B immunisations been given?

Please check HBsAg & anti-HBc (and Hep C Ab) and if no evidence of Hep B infections then a course of Hepatitis B vaccines to be given and HBsAb level checked thereafter.

 If YES has HBsAb level been checked?
 YES
 Enter Level \_\_\_\_\_\_

 NO
 Please check and discuss level with responsible physician.

 •
 If level < 10 IU/ml then please check HBsAg and anti-HBc</td>

 •
 If both negative organise full course of repeat Hepatitis B immunisation - GREEN BOOK/CHIVA Guideline

 •
 If level 10-100 IU/ml then organise for a single booster Hepatitis B immunisation Green Book/CHIVA Guideline

 •
 If level > 100 IU/ml then no further action required 

If more than 5 years since primary course of Hepatitis B immunisation, has a single booster been given (one time only)? Green Book /CHIVA Guideline

Date of Booster: \_\_\_ / \_\_\_ / \_\_\_\_

If not yet done please organise

Date contacted GP:	/		1
Date contacted GF.	/	/	

Review: September 2026 NSD610-019 V3

Name	CHI Number
DOB	Date of Review

#### Immunisation (continued) 1.

#### Influenza

Annual influenza immunisation	YES		No further action required
	NO		Please organise with GP
	Date of	contacte	d GP://
<u>Pneumococcal</u>			
If the child did not receive immunisations a	s per th	e UK im	munisation schedule did they receive Prevnar 13?
	YES		No further action required
	NO		Please arrange for Prevnar 13 immunisation x 2 (1 month apart) with GP if age < 5years
	Date	contacte	d GP://
<u>Measles/MMR</u>			
Measles Immunisation	YES		No further action required
	NO		Please organise with GP
	Date	contacte	d GP://
Measles IgG detected	YES		
	NO		
<u>COVID-19 (over 5yrs)</u>			
COVID-19 vaccination	YES		No further action required
	NO		Please organise with GP
	Date	contacte	d GP://

SPAIIN Guidance for the Annual Review of Children and Adolescents' Living with HIV

Name	CHI Number
DOB	Date of Review

#### 2. Metabolic Section

#### Bone health and vitamin D status

Annual autumn / winter check – DATE: \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Results:

Ca (adjusted)	
PO4	
250VitD	
PTH	
ALP	
Creatinine	
Urea	

#### VITAMIN D

VIT D dose dispensed with each 3 monthly prescription of ARVs:

#### Lipids and Vascular Health

Once yearly cholesterol, HDL, LDL and triglycerides (non-fasting) – date:

Total Cholesterol:

LDL Cholesterol:

If cholesterol > 4.4, or LDL cholesterol > 2.9 refer to dietician and arrange repeat testing (fasting) within 6 months.

If cholesterol > 5.2, or LDL cholesterol > 3.4 obtain fasting measurement and discuss with responsible clinician.

Does the Patient smoke?	YES
	NO
	Patient BP mmHg

Name	CHI Number
DOB	Date of Review

#### **Renal Health**

Is the child / adolescent currently on tenofovir / atripla / truvada / eviplera?

NO	
YES	Has the child / adolescent had a least 2 documented normal plasma phosphate urine protein / creatinine ratio checked YES
	Plasma phosphate levels _mmol/l
	DATE://
	Urine protein / creatinine ratio checked

DATE: \_\_\_/ \_\_\_/

SPAIIN Guidance for the Annual Review of Children and Adolescents' Living with HIV

DOB Date of Review	

## 3. Growth and Puberty Section

Height	
Weight	
BMI = Height (cm) / Weight (kg)	

If BMI > 25 then refer to dietician / local weight loss support program (e.g. weigh to go). If height or weight below 2<sup>nd</sup> centile or falling through centiles then discuss with responsible clinician. **Plot on growth chart within notes** 

#### Puberty – staged from 12 years of age – as assessed by a physician

✓ List	Boys – De	velopment of external genitalia	
	Stage 1:	Prepubertal	
	Stage 2:	Enlargement of scrotum and testes; scrotum skin reddens and changes in texture	
	Stage 3:	Enlargement of penis (length at first); further growth of testes	
	Stage 4:	Increased size of penis with growth in breadth and development of glands; testes	
		and scrotum larger, scrotum skin darker	
	Stage 5:	Adult genitalia	
✓ List	Girls – Bre	east Development	
	Stage 1:	Prepubertal	
-	Stage 2:	Breast bud stage with elevation of breast and papilla; enlargement of areola	
-	Stage 3:	Further enlargement of breast and areola; no separation of their contour	
-	Stage 4:	Areola and papilla form a secondary mound above level of breast	
	Stage 5:	Mature stage; projection of papilla only, related to recession of areola	
✓ List	Boys and	Girls – Pubic Hair	
	Stage 1:	Prepubertal (can see vellus hair similar to abdominal wall)	
	Stage 2:	Sparse growth of long, slightly pigmented hair, straight or curled, at base of penis o	
		along labia	
	Stage 3:	Darker, coarser and more curled hair, spreading sparsely over junction of pubes	
	Stage 4:	Hair adult in type, but covering smaller area than in adult; no spread to medial surface of thighs	
	Stage 5:	Adult in type and quantity, with horizontal distribution ("feminine")	

Indications for referral to endocrinology: no signs of secondary sexual characteristics in girls aged 13 and boys aged 14 or more practically if the patient is concerned, particularly if there is no family history of pubertal delay.

SPAIIN Guidance for the Annual Review of Children and Adolescents' Living with HIV

Name	CHI Number
DOB	Date of Review

# 4. Neurodevelopment and Education Section

Does the child's carer / young person have specific concerns in the following areas?

a)	Mobility	YES [	NO	
b)	Vision	YES	NO	
c)	Hearing	YES	NO	
d)	Speech	YES	NO	
e)	Understanding	YES	NO	
f)	School Progress	YES	NO	
g)	Behaviour	YES	NO	
h)	Routines	YES	NO	
i)	Memory	YES	NO	
j)	Concentration	YES	NO	
k)	Activity / Energy Levels	YES	NO	
I)	Emotional	YES	NO	

Please note any specific concerns.

#### **Educational History**

School Year at Present

Number of Previous Schools:

Does the child receive any additional help in School?

If Other Please Describe:

Name	CHI Number
DOB	Date of Review

#### 5. **Disclosure and Adherence Section**

Level of child's k	knowledge: None or Little Partial	Full
Date:	Name of parent / Carer present:	Description of Plan:
//	•	
	•	
	•	
Standard proc	ess	
Date	List interventions or approaches	Achieved
	agreed	
	1.	YES Date: / /
//		
		NO Please follow up
		Date: / /
//	2.	YES Date: / /
		NO Please follow up
		Date: / /
//	3.	YES Date: / /
		NO Please follow up
		Date: / /
//	4.	YES Date: / /
		NO Please follow up
		Date: / /

SPAIIN Guidance for the Annual Review of Children and Adolescents' Living with HIV

Name	CHI Number
DOB	Date of Review

#### 5. Disclosure and Adherence Section (continued)

Extra Support (e	e.g. Psychologist)	
//	5.	YES Date: / /
		NO Please follow up
		Date://
//	6.	YES Date: / /
		NO Please follow up
		Date://
Naming Convers	sation: Persons present	
//	7. •	YES Date: / /
	•	NO Please follow up
	•	Date: / /
Child's response	/ comments	
//	8. •	YES Date: / /
	•	NO Please follow up
	•	Date: / /

If the child / adolescent is aware of their diagnosis and on / about to start therapy have the following concepts been discussed with the child / adolescent;

Viral suppression rather than cure Recovery of the immune system and potential for long and health life Lifelong adherence to drugs Viral resistance and its relationship to adherence Discussion and understanding on the concept of U=U

YES	NO	
YES	NO	

SPAIIN Guidance for the Annual Review of Children and Adolescents' Living with HIV

Name CHI Number	
DOB Date of Revi	ew

## 5. Disclosure and Adherence Section (Continued)

Ask the person responsible for administering the medication (i.e. child / adolescent or carer) to list the current regimen:

Drug	Frequency	Amount tabs / mls
Drug	Frequency	Amount tabs / mls
Drug	Frequency	Amount tabs / mls
Drug	Frequency	Amount tabs / mls
Has the child / adolescent had a repeatedly current ARV regimen)?	undetectable viral load over the last YES NO	year (6 months after starting
Who is responsible for administering the me	edication?	
Child / Adolescent Parent	Other (Specify)	
Does the child / adolescent / carer use a do	sette box? YESNO	
Who loads the dosette box?		
Child / Adolescent Parent	Other (Specify)	
At what times of the day does the child / ad	olescent take medication?	
Does the child / adolescent take medication	is with food?	
	YES NO	

SPAIIN Guidance for the Annual Review of Children and Adolescents' Living with HIV

Name	CHI Number
DOB	Date of Review

### 5. Disclosure and Adherence Section (Continued)

If the child is > 13 years of age and the parents takes full responsibility for administering the medication, discuss with the parent when they expect the adolescent to start to take responsibility for the medication. Discuss strategies for gradual handover of responsibility and continuing support from parent.

Notes:

How many doses of medicine have been missed over the last 3 months?

Does the child / adolescent / carer have a plan for what to do when medications are missed or if they are away from home and do not want to disclose their medications?

Notes:

Is the child / adolescent / carer aware of or have concerns regarding any potential side – effects of medication?

Notes:

SPAIIN Guidance for the Annual Review of Children and Adolescents' Living with HIV

Name	CHI Number
DOB	Date of Review

#### 6. Sexual Health

Please note that this may also be covered by the sexual health advisor attached to the adolescent clinic and documented in that circumstance.

#### If adolescent is over 13 years of age, have they received sexual health advice?

YES	No further action required
NO	Please discuss with consultant in charge

# Summary / Plan of Action:

#### Chart with 3 / 12 slots

Date	Action	Plan
//	e.g. 1, 3, 5	
_/_/		
_/_/		
_/_/		
_/_/		
_/_/		
//		
//		

#### **Further Comments:**